Clearside Biomedical, Inc. (CLSD) by event type
CLSD moves most on analyst downgrades — a median of -4.54% at 30 minutes across 19 measured events. Each row is measured over the last three years and read against the price at its own news timestamp. Back to the CLSD overview →
How CLSD reacts across 3 measured event types.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades 2,582 of 2,603 | 19 | -4.54% | 21% | -18.06% |
| Coverage initiations 2,212 of 2,283 | 17 | -1.90% | 24% | -2.59% |
| Rating reiterations 335 of 3,522 | 53 | +0.27% | 57% | -0.97% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The rank under each event type orders every name measured for it by median 30-min reaction, most positive first — so a low rank on a downgrade means this name falls harder than most, not that it moves less. Names with an identical median share a rank; a name the cross-section does not carry shows no rank rather than a guessed one. 3 further classes were observed with fewer than 10 measured events and are not published.
That’s how CLSD usually reacts — get an email when it moves on news →Every name measured for these event types: Analyst downgrades → · Coverage initiations → · Rating reiterations → · CLSD overview →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
| BeyondSpring, Inc. - Ordinary Shares (BYSI) | 146 | 0.00% | 49% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
| GlycoMimetics, Inc. (GLYC) | 144 | +0.53% | 54% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.